SLC5A2 and type 2 diabetes mellitus: Moreover, these guidelines recommend GLP-1 receptor agonists and SGLT2 inhibitors as first-line glucose-lowering treatments in patients with type 2 diabetes and CVD, or at high to very high CV risk, to reduce CV events and mortality [4].